RecruitingPhase 1NCT05414500

Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides

Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF)

Sponsor

University of Alabama at Birmingham

Enrollment

10 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Mycosis Fungoides Cutaneous T Cell Lymphoma

Summary

This is an open label, single center, non-randomized dose de-escalation phase I study of combination of BV and Mogamulizumab. The primary objective of the study is to assess the safety and tolerability of the combination. The primary objective is also to explore safe dose of combination for future expansion.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a combination of two immunotherapy drugs — mogamulizumab and brentuximab vedotin — for people with certain types of rare skin lymphomas, specifically Sezary Syndrome and Mycosis Fungoides. These are cancers that affect white blood cells and show up primarily in the skin. **You may be eligible if...** - You are 18 or older - You have been diagnosed with Sezary Syndrome or Mycosis Fungoides (confirmed by a pathologist) - Your disease is at an advanced or progressed stage - You are well enough to carry out daily activities - Your kidneys, liver, heart, and blood counts are functioning well enough **You may NOT be eligible if...** - You have received mogamulizumab or brentuximab vedotin before - You have active or uncontrolled infections - You have significant heart, liver, or kidney disease - You have an autoimmune condition requiring treatment - You are pregnant or breastfeeding - You have had a stem cell transplant recently Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.